{"key":"tesofensine","slug":"tesofensine","name":"Tesofensine","other_names":[],"kind":"single","area":{"slug":"metabolic","name":"Metabolic"},"classification":"Monoamine reuptake inhibitor (not a peptide)","standing":{"id":"human-studies","label":"Studied in people","rank":2},"summary":"A small molecule that blocks the reuptake of noradrenaline, dopamine and serotonin, studied in obesity trials. It is not a peptide.","cas_number":null,"molecular_formula":null,"molecular_weight":null,"components":[],"has_article":false,"pubmed":{"papers":52,"in_humans":40,"clinical_trials":11},"retired":false,"updated_at":"2026-11-19T00:17:24.814Z","url":"https://pepts.wiki/compounds/tesofensine","article":null,"evidence":{"query":"(\"Tesofensine\"[tiab])","fetched_at":"2026-11-16T23:08:17.702Z","counts":{"rcts":11,"human":40,"total":52,"reviews":17,"clinicalTrials":11},"years":[{"year":2012,"count":3},{"year":2013,"count":7},{"year":2014,"count":3},{"year":2015,"count":1},{"year":2016,"count":1},{"year":2017,"count":0},{"year":2018,"count":2},{"year":2019,"count":1},{"year":2020,"count":2},{"year":2021,"count":0},{"year":2022,"count":1},{"year":2023,"count":0},{"year":2024,"count":1},{"year":2025,"count":2},{"year":2026,"count":1}],"top":[{"doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/19824222/","kind":"rct","pmid":"19824222","year":2009,"title":"[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication]","venue":"Ugeskrift for laeger","authors":"Nielsen AL, Larsen TM, Madsbad S, et al."},{"doi":"10.1530/EJE-21-0972","url":"https://pubmed.ncbi.nlm.nih.gov/35294397/","kind":"rct","pmid":"35294397","year":2022,"title":"Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity","venue":"European journal of endocrinology","authors":"Huynh K, Klose M, Krogsgaard K, et al."},{"doi":"10.1038/clpt.2010.67","url":"https://pubmed.ncbi.nlm.nih.gov/20520602/","kind":"rct","pmid":"20520602","year":2010,"title":"Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users","venue":"Clinical pharmacology and therapeutics","authors":"Schoedel KA, Meier D, Chakraborty B, et al."},{"doi":"10.1038/oby.2011.197","url":"https://pubmed.ncbi.nlm.nih.gov/21720440/","kind":"rct","pmid":"21720440","year":2012,"title":"The effect of tesofensine on appetite sensations","venue":"Obesity (Silver Spring, Md.)","authors":"Gilbert JA, Gasteyger C, Raben A, et al."},{"doi":"10.1016/S0140-6736(08)61525-1","url":"https://pubmed.ncbi.nlm.nih.gov/18950853/","kind":"rct","pmid":"18950853","year":2008,"title":"Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial","venue":"Lancet (London, England)","authors":"Astrup A, Madsbad S, Breum L, et al."},{"doi":"10.1208/s12248-009-9164-6","url":"https://pubmed.ncbi.nlm.nih.gov/20077053/","kind":"rct","pmid":"20077053","year":2010,"title":"Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine","venue":"The AAPS journal","authors":"Lehr T, Staab A, Trommeshauser D, et al."},{"doi":"10.1371/journal.pone.0300544","url":"https://pubmed.ncbi.nlm.nih.gov/38656972/","kind":"study","pmid":"38656972","year":2024,"title":"Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons","venue":"PloS one","authors":"Perez CI, Luis-Islas J, Lopez A, et al."},{"doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/19777399/","kind":"review","pmid":"19777399","year":2009,"title":"Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity","venue":"Current opinion in investigational drugs (London, England : 2000)","authors":"Bello NT, Zahner MR"},{"doi":"10.1038/npp.2010.16","url":"https://pubmed.ncbi.nlm.nih.gov/20200509/","kind":"study","pmid":"20200509","year":2010,"title":"Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat","venue":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","authors":"Axel AM, Mikkelsen JD, Hansen HH"},{"doi":"10.1001/archneur.65.5.577","url":"https://pubmed.ncbi.nlm.nih.gov/18474731/","kind":"rct","pmid":"18474731","year":2008,"title":"Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study","venue":"Archives of neurology","authors":"Rascol O, Poewe W, Lees A, et al."}]},"library_version":"183:2026-11-17T11:05:42.386Z","attribution":"Data from Pepts.wiki (https://pepts.wiki), CC BY 4.0. Link back to the compound's page.","notice":"We are not doctors, and nothing on Pepts.wiki is medical advice or a recommendation to use anything. The wiki sets out what studies measured, as clearly and evenly as it can, so you can make better-informed decisions. Always consult a medical professional before acting on anything you read here."}